Methods for treatment of m-TOR inhibitor-associated stomatitis
View Patent ↗Embodiments of the invention relate to a method for the treatment of mIAS or prevention of symptoms associated with mIAS in a patient in need thereof comprising administering to a patient in need thereof an amount of a composition comprising extracts of the plant species Sambucus nigra, Echinacea purpurea , and Centella asiatica . Optionally the ratio of Sambucus nigra, Echinacea purpurea and Centella asiatica is about 7:1:2. Further embodiments relate to use of extracts of the plant species Sambucus nigra, Echinacea purpurea , and Centella asiatica for the manufacture of a medicament for the treatment of mIAS or prevention of symptoms associated with mIAS in a patient in need thereof.
1. A method for treating mammalian target of rapamycin (mTOR) inhibitor associated stomatitis (mIAS) in a patient in need thereof, comprising administering an effective amount of a composition comprising Sambucus nigra, Echinacea purpurea , and Centella asiatica extracts to said patient.
2. The method according to claim 1 , wherein the ratio of Sambucus nigra, Echinacea purpurea and Centella asiatica is about 7:1:2.
3. The method according to claim 1 , wherein the patient is receiving an mTOR inhibitor treatment.
4. The method according to claim 3 , wherein the patient is receiving an mTOR inhibitor treatment for cancer or organ transplantation.
5. The method according to claim 1 , wherein the composition is in the form of an oral rinse.
6. The method according to claim 1 , wherein the composition is in the form of an oral patch.
7. The method according to claim 1 , wherein the composition is administered to the patient after an mIAS symptom appears.
8. The method according to claim 3 , wherein the composition is administered in combination with an mTOR inhibitor.
9. The method according to claim 1 , wherein the amount of the composition is effective to increase TIMP-3 levels in the patient.
10. The method according to claim 1 , wherein the composition further comprises at least one pharmaceutically acceptable excipient.
11. The method according to claim 5 , wherein the composition further comprises propylene glycol.
12. The method according to claim 11 , wherein the weight ratio of the extracts and propylene glycol is about 1 to 4.
13. The method according to claim 8 , wherein the mTOR inhibitor is selected from the group consisting of: rapamycin, rapamycin analogs, temsirolimus, everolimus, ridaforolimus, sirolimus and deforolimus.